Open Nav

Elevian, Inc.

  • Mark Allen, Elevian, Inc.

Seeking Investment

  • Date:Thursday, October 18
  • Time:11:00 AM - 11:15 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:At Elevian, we develop new medicines to restore regenerative capacity, with the potential to prevent and treat many age-related diseases. Our scientific cofounders, working at Stanford and Harvard, discovered the regenerative effects of young blood. They went on to discover that replenishing a single circulating protein (GDF11) in aged animals to youthful levels can regenerate the heart, brain, muscle and other tissues. We are developing novel therapeutics that modulate GDF11 to treat and prevent age-related diseases including cardiovascular, metabolic, neurodegenerative, and musculoskeletal diseases. We have exclusive worldwide license to the GDF11-related patent portfolio from Harvard and its research partners.
  • Company
  • Company HQ City:Allston
  • Company HQ Country:United States
  • Company HQ State:Massachusetts       
  • CEO/Top Company Official:Mark Allen
  • Year Founded:2017
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :recombinant human GDF11
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Previous and Current Investors:BOLD Capital, Stanford StartX Fund, Kizoo Technology Ventures, Thynk Capital, Longevity Fund, WTI
  • Size of Last Investment Round:$5,500,000
  • Total Amount Raised to Date, In All Rounds:$5,500,000
Mark Allen
Elevian, Inc.